OmniAb, Inc.
HealthcareNASDAQ:OABI · NASDAQ Global Market
-$0.07 today
Vol 0.21M · Avg 0.65M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-24.3%
avg -13.4%
ROIC
-24.2%
avg -12.5%
ROA
-21.5%
avg -11.3%
Analysis
ROA is currently the strongest return metric at -21.5% versus its period average of -11.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Matthew W. Foehr | President, Chief Executive Officer & Director | $1.07M | — | 53 | $4.44M | 3.73% |
Charles S. Berkman | Chief Legal Officer & Secretary | $742,065.00 | — | 57 | $111,042.00 | 0.09% |
Kurt A. Gustafson | Executive Vice President of Finance & Chief Financial Officer | $730,741.00 | — | 58 | $268,396.00 | 0.23% |
Bill Harriman | Senior Vice President of Antibody Discovery | — | — | — | — | — |
Christel Iffland | Senior Vice President of Antibody Technologies | — | — | — | — | — |
Todd Pettingill | Vice President of Business Development & Strategy | — | — | — | — | — |
Cia McCaffrey | Senior Vice President of People & Talent | — | — | — | — | — |
Yasmina Noubia Abdiche | Senior Vice President of Exploratory Research | — | — | — | — | — |
Bob Chen | Senior Vice President of Discovery Systems | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
2
$107,706.87
Sells
12
$283,036.05
Net Sentiment
$175,329.18
Net selling
Most Active
GUSTAFSON KURT A
4 transactions
1–10 of 14
Analysis
Insiders reported 2 buys worth $107,706.87 and 12 sells worth $283,036.05 over the last 12 months. That adds up to net selling of $175,329.18. GUSTAFSON KURT A was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | +13.7% | +18.9% (7yr)2 analysts |
| Net Income | N/A | N/A | N/A | N/A2 analysts |
| EBIT | N/A | N/A | N/A | N/A2 analysts |
Analysis
Recent growth has been strongest in Revenue at +13.7% over three years. Forward estimates point to Revenue at +18.9% (7yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
C4 Therapeutics, Inc.
NASDAQ:CCCC
$323.03M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
Codexis, Inc.
NASDAQ:CDXS
$218.15M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
$150.58M
Protara Therapeutics, Inc.
NASDAQ:TARA
$150.50M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Invivyd, Inc.
NASDAQ:IVVD
$102.20M
Sangamo Therapeutics, Inc.
NASDAQ:SGMO
$64.96M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
Who manages OABI?
OmniAb, Inc. (OABI) lists 9 active executives. The top listed executive is Matthew W. Foehr, President, Chief Executive Officer & Director.
Are OABI insiders buying or selling?
Recent insider activity shows net buying of $21.12M.
Explore More
Continue the stock analysis
Jump to another research area for this company.